NASDAQ: TCRTAlaunos Therapeutics Inc Stock
$1.20+0.11 (+10.09%)
Updated Apr 23, 2024
TCRT Price
$1.20
Fair Value Price
$0.37
Market Cap
$19.21M
52 Week Low
$0.66
52 Week High
$10.47
P/E
-0.55x
P/B
3.05x
P/S
3,392.62x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.00k
Earnings
-$35.14M
Gross Margin
100%
Operating Margin
-664,380%
Profit Margin
-702,800%
Debt to Equity
0.31
Operating Cash Flow
-$30M
Beta
1.37
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
TCRT Overview
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TCRT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TCRT ($1.20) is overvalued by 220.84% relative to our estimate of its Fair Value price of $0.37 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TCRT ($1.20) is not significantly undervalued (220.84%) relative to our estimate of its Fair Value price of $0.37 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TCRT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TCRT due diligence checks available for Premium users.
Be the first to know about important TCRT news, forecast changes, insider trades & much more!
TCRT News
Valuation
TCRT fair value
Fair Value of TCRT stock based on Discounted Cash Flow (DCF)
Price
$1.20
Fair Value
$0.37
Overvalued by
220.84%
TCRT ($1.20) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TCRT ($1.20) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TCRT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TCRT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.55x
Industry
16.46x
Market
41.92x
TCRT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.05x
Industry
5.93x
TCRT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TCRT's financial health
Profit margin
Revenue
$1.0k
Net Income
-$7.8M
Profit Margin
-784,300%
TCRT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TCRT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$8.3M
Liabilities
$2.0M
Debt to equity
0.31
TCRT's short-term assets ($8.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TCRT's short-term assets ($8.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TCRT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
TCRT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.4M
Investing
$1.5M
Financing
$0.0
TCRT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TCRT vs Biotech Stocks
Alaunos Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.